Table 1.
Intravenous C16 and Ang-1 enhanced the efficacy of PMSC therapy for restoring CSEP and CMEP latency and amplitude in rats with EAE.
| 3 weeks pi | CSEP Latency (ms) | ||
|---|---|---|---|
| Group | N | P | Wave amplitude (Vmean ± SD) |
| Normal | 11.6 ± 0.20** (ES = 8.14, P = 0.003) |
16.22 ± 0.24** (ES = 6.59, P = 0.0027) |
2.15 ± 0.36* (ES = 10.29, P = 0.011) |
| Vehicle | 18.38 ± 0.89 | 25.32 ± 1.15 | 0.78 ± 0.06 |
| PMSCs | 13.44 ± 1.54** (ES = 0.76, P = 0.004) |
19.45 ± 0.85** (ES = 2.87, P = 0.001) |
2.34 ± 0.68* (ES = 3.35, P = 0.03) |
| P + C + A | 12.08 ± 0.99** (ES = 3.55, P = 0.0006; vs. PMSCs: ES = 0.4, P = 0.13) |
17.31 ± 0.42**& ES = 5.34, P = 0.0001; vs. PMSCs: ES = 2.38, P = 0.009) |
2.07 ± 0.33* (ES = 11.47, P = 0.0109; vs. PMSCs: ES = 0.47, P = 0.28) |
| 3 weeks pi | CMEP Latency (ms) | ||
| Group | Wave amplitude (V mean ± SD) | ||
| Normal | 5.2 ± 0.14** (ES = 9.09, P = 0.002) |
4.56 ± 0.23** (ES = 71.15, P < 0.0001) | |
| Vehicle | 13.24 ± 0.93 | 0.54 ± 0.06 | |
| PMSCs | 5.81 ± 0.22** (ES = 8.13, P < 0.0001) |
4.45 ± 1.11* (ES = 3.16, P = 0.012) | |
| P + C + A | 5.83 ± 0.34** (ES = 7.55, P = 0.0001; vs. PMSCs: ES = 0.12, P = 0.46) |
5.69 ± 0.76** (ES = 8.86, P = 0.004; vs. PMSCs: ES = 0.69, P = 0.09) | |
| 8 weeks pi | CSEP Latency (ms) | ||
| Groups | N | P | Wave amplitude (V mean ± SD) |
| Normal | 11.22 ± 0.94** (ES = 2.53, P = 0.0002) |
16.76 ± 1.08** (ES = 3.34, P = 0.0001) |
2.86 ± 0.33** (ES = 16.26, P = 0.005) |
| Vehicle | 27.22 ± 2.33 | 32.98 ± 1.92 | 1.01 ± 0.07 |
| PMSCs | 16.85 ± 1.68** (ES = 2.16, P = 0.0017) |
22.41 ± 1.48** (ES = 1.8, P = 0.0008) |
2.69 ± 0.36** (ES = 12.49, P = 0.0078) |
| P + C + A | 14.32 ± 1.35** (ES = 1.77, P = 0.0006; vs. PMSCs: ES = 0.54, P = 0.06) |
19.01 ± 1.78**& (ES = 2.04, P = 0.0004; vs. PMSCs: ES = 0.63, P = 0.03) |
2.50 ± 0.14** (ES = 60.82, P < 0.0001; vs. PMSCs: ES = 1.27, P = 0.22) |
| 8 weeks pi | CMEP Latency (ms) | ||
| Groups | Wave amplitude (V mean ± SD) | ||
| Normal | 5.32 ± 0.43** (ES = 52.22, P < 0.0001) |
7.39 ± 1.31** (ES = 4.19, P = 0.005) | |
| Vehicle | 17.28 ± 0.21 | 0.17 ± 0.09 | |
| PMSCs | 6.34 ± 0.88** (ES = 13.37, P < 0.0001) |
4.36 ± 1.16* (ES = 3.1, P = 0.012) | |
| P + C + A | 5.52 ± 1.45** (ES = 5.48, P = 0.003; vs. PMSCs: ES = 0.29, P = 0.22) |
4.73 ± 0.55** (ES = 14.68, P = 0.0002; vs. PMSCs: ES = 0.22, P = 0.21) | |
*P < 0.05, **P < 0.01 vs. vehicle; &P < 0.05 vs. PMSCs. N, negative deflection; P, positive deflection; pi, post-immunization.